LeMaitre Vascular (NASDAQ:LMAT) Releases FY24 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.73-1.84 for the period, compared to the consensus estimate of $1.65. The company issued revenue guidance of $212.7-217.3 million, compared to the consensus revenue estimate of $211.69 million. LeMaitre Vascular also updated its Q2 guidance to $0.45-0.50 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on LMAT shares. KeyCorp started coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a sector weight rating for the company. StockNews.com upgraded LeMaitre Vascular from a hold rating to a buy rating in a report on Friday. JMP Securities lifted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research note on Friday. Barrington Research increased their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a research report on Friday. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and raised their target price for the company from $59.00 to $75.00 in a report on Friday, April 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $73.83.

LeMaitre Vascular Trading Up 11.2 %

NASDAQ:LMAT traded up $7.45 during midday trading on Friday, hitting $74.22. 329,984 shares of the company traded hands, compared to its average volume of 110,751. The firm’s fifty day moving average is $65.93 and its 200-day moving average is $58.85. The firm has a market capitalization of $1.67 billion, a P/E ratio of 49.15, a P/E/G ratio of 3.20 and a beta of 0.88. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.75%. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same quarter in the prior year, the firm posted $0.27 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. On average, research analysts expect that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a $0.16 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 36,600 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the sale, the chief executive officer now directly owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares in the company, valued at $358,357.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The disclosure for this sale can be found here. In the last three months, insiders sold 114,036 shares of company stock valued at $7,873,749. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.